Antibiotic-resistant infections persist because bacteria evolve mechanisms that deactivate or evade drugs originally designed to kill them. Phage engineering repurposes bacteriophages—viruses that naturally infect bacteria—to attack resistance at its source. Work by Robert J. Citorik, Melanie Mimee, and Timothy K. Lu at the Massachusetts Institute of Technology demonstrated that phage-derived delivery systems can carry sequence-specific antimicrobials, showing a practical route to selectively remove resistance genes. This approach leverages the phage life cycle while minimizing collateral damage to beneficial microbes.
Engineered strategies and mechanisms
Engineered phages can change three core variables: host specificity, killing mechanism, and genetic payload. Laboratory teams alter receptor-binding proteins to broaden or retarget host range, convert temperate phages into obligately lytic variants to ensure bacterial killing, and load phages with CRISPR-Cas systems or toxin genes to inactivate resistance determinants. Anthony C. Fischetti at Rockefeller University has advanced the related use of phage-derived lysins—enzybiotics—which enzymatically break bacterial cell walls and can work against Gram-positive pathogens where antibiotics fail. Such precision reduces selection on non-target commensals compared with broad-spectrum antibiotics, but it does not eliminate ecological consequences.
Clinical, cultural, and ecological implications
Clinical translation has moved beyond theory. Graham F. Hatfull at the University of Pittsburgh and colleagues contributed expertise in assembling therapeutic phage cocktails and in adapting phages for compassionate-use treatments, illustrating feasibility in complex human infections. Laurent Debarbieux at Institut Pasteur provided preclinical evidence of efficacy and safety in animal models, supporting progression toward regulated trials. The practice also carries cultural and territorial dimensions: centers such as the Eliava Institute in Tbilisi, Georgia, reflect long-standing regional experience with phage therapy and are influential in compassionate-use practice where regulatory frameworks differ.
Phage engineering faces consequences and limits: bacteria can evolve phage resistance, environmental release raises stewardship questions, and regulatory pathways remain nascent. Combining engineered phages with antibiotics or using rotating phage cocktails can delay resistance and preserve community-level benefits. Ultimately, robust surveillance, multidisciplinary clinical trials, and equitable access will determine whether engineered phages become a mainstream complement to antibiotics.